The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management.
To estimate the incremental net benefits (INBs) of a hypothetical ideal vaccine with all of the advantages and no disadvantages of existing oral and inactivated poliovirus vaccines compared with current vaccines available for future outbreak response.



INB estimates based on expected costs and polio cases from an existing global model of long-term poliovirus risk management.



Excluding the development costs, an ideal poliovirus vaccine could offer expected INBs of US$1.6 billion. The ideal vaccine yields small benefits in most realizations of long-term risks, but great benefits in low-probability-high-consequence realizations.



New poliovirus vaccines may offer valuable insurance against long-term poliovirus risks and new vaccine development efforts should continue as the world gathers more evidence about polio endgame risks.
Kid Risk, Inc., 10524 Moss Park Rd., Ste. 204-364, Orlando, FL 32832, USA.
Radboud J
RJ
Duintjer Tebbens
Kid Risk, Inc., 10524 Moss Park Rd., Ste. 204-364, Orlando, FL 32832, USA.
Kimberly M
KM
Thompson
D006801:Humans; D008962:Models, Theoretical; D011051:Poliomyelitis / Q000191:economics / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D017955:Poliovirus / Q000145:classification / Q000235:genetics / Q000276:immunology*; D023321:Poliovirus Vaccines / Q000008:administration & dosage / Q000191:economics / Q000276:immunology*; D012308:Risk Management; D014611:Vaccination / Q000191:economics
D023321:Poliovirus Vaccines
OPV cessation; dynamic modeling; eradication; polio; risk management; vaccine development